189 related articles for article (PubMed ID: 23382118)
1. Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes.
Birks DK; Donson AM; Patel PR; Sufit A; Algar EM; Dunham C; Kleinschmidt-DeMasters BK; Handler MH; Vibhakar R; Foreman NK
Pediatr Blood Cancer; 2013 Jul; 60(7):1095-102. PubMed ID: 23382118
[TBL] [Abstract][Full Text] [Related]
2. Identification of RPL5 and RPL10 as novel diagnostic biomarkers of Atypical teratoid/rhabdoid tumors.
Ren Y; Tao C; Wang X; Ju Y
Cancer Cell Int; 2018; 18():190. PubMed ID: 30479569
[TBL] [Abstract][Full Text] [Related]
3. SMARCB1-deficient Tumors of Childhood: A Practical Guide.
Pawel BR
Pediatr Dev Pathol; 2018; 21(1):6-28. PubMed ID: 29280680
[TBL] [Abstract][Full Text] [Related]
4. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.
Darr J; Klochendler A; Isaac S; Geiger T; Eden A
Mol Cancer; 2015 Sep; 14():167. PubMed ID: 26370283
[TBL] [Abstract][Full Text] [Related]
5. Rhabdoid tumors: an initial clue to the role of chromatin remodeling in cancer.
Lee RS; Roberts CW
Brain Pathol; 2013 Mar; 23(2):200-5. PubMed ID: 23432645
[TBL] [Abstract][Full Text] [Related]
6. SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors.
Panwalkar P; Pratt D; Chung C; Dang D; Le P; Martinez D; Bayliss JM; Smith KS; Adam M; Potter S; Northcott PA; Mascarenhas L; Shows J; Pawel B; Margol A; Huang A; Judkins AR; Venneti S
Neuro Oncol; 2020 Jun; 22(6):785-796. PubMed ID: 31912158
[TBL] [Abstract][Full Text] [Related]
7. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
Kuwahara Y; Wei D; Durand J; Weissman BE
Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
[TBL] [Abstract][Full Text] [Related]
8. Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome.
Foulkes WD; Kamihara J; Evans DGR; Brugières L; Bourdeaut F; Molenaar JJ; Walsh MF; Brodeur GM; Diller L
Clin Cancer Res; 2017 Jun; 23(12):e62-e67. PubMed ID: 28620006
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetics of atypical teratoid/rhabdoid tumor.
Biegel JA
Neurosurg Focus; 2006 Jan; 20(1):E11. PubMed ID: 16459991
[TBL] [Abstract][Full Text] [Related]
10. Integrated genomics has identified a new AT/RT-like yet INI1-positive brain tumor subtype among primary pediatric embryonal tumors.
Ho DM; Shih CC; Liang ML; Tsai CY; Hsieh TH; Tsai CH; Lin SC; Chang TY; Chao ME; Wang HW; Wong TT
BMC Med Genomics; 2015 Jun; 8():32. PubMed ID: 26109171
[TBL] [Abstract][Full Text] [Related]
11. Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.
Tegeder I; Thiel K; Erkek S; Johann PD; Berlandi J; Thatikonda V; Frühwald MC; Kool M; Jeibmann A; Hasselblatt M
J Neurooncol; 2019 Jan; 141(1):43-55. PubMed ID: 30446899
[TBL] [Abstract][Full Text] [Related]
12. Rhabdoid tumors: integrating biological insights with clinical success: a report from the SMARCB1 and Rhabdoid Tumor Symposium, Paris, December 12-14, 2013.
Bourdeaut F; Chi SN; Frühwald MC
Cancer Genet; 2014 Sep; 207(9):346-51. PubMed ID: 25468731
[TBL] [Abstract][Full Text] [Related]
13. Study of the gene expression and microRNA expression profiles of malignant rhabdoid tumors originated in the brain (AT/RT) and in the kidney (RTK).
Grupenmacher AT; Halpern AL; Bonaldo Mde F; Huang CC; Hamm CA; de Andrade A; Tomita T; Sredni ST
Childs Nerv Syst; 2013 Nov; 29(11):1977-83. PubMed ID: 23999875
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of SMARCB1 constitutional abnormalities including mosaicism in malignant rhabdoid tumors.
Shirai R; Osumi T; Terashima K; Kiyotani C; Uchiyama M; Tsujimoto S; Yoshida M; Yoshida K; Uchiyama T; Tomizawa D; Shioda Y; Sekiguchi M; Watanabe K; Keino D; Ueno-Yokohata H; Ohki K; Takita J; Ito S; Deguchi T; Kiyokawa N; Ogiwara H; Hishiki T; Ogawa S; Okita H; Matsumoto K; Yoshioka T; Kato M
Eur J Hum Genet; 2020 Aug; 28(8):1124-1128. PubMed ID: 32218533
[TBL] [Abstract][Full Text] [Related]
15. Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors.
Birks DK; Kleinschmidt-DeMasters BK; Donson AM; Barton VN; McNatt SA; Foreman NK; Handler MH
Brain Pathol; 2010 Jan; 20(1):140-50. PubMed ID: 19220299
[TBL] [Abstract][Full Text] [Related]
16. Biology and Treatment of Rhabdoid Tumor.
Geller JI; Roth JJ; Biegel JA
Crit Rev Oncog; 2015; 20(3-4):199-216. PubMed ID: 26349416
[TBL] [Abstract][Full Text] [Related]
17. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
[TBL] [Abstract][Full Text] [Related]
18. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
[TBL] [Abstract][Full Text] [Related]
19. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression.
Hasselblatt M; Gesk S; Oyen F; Rossi S; Viscardi E; Giangaspero F; Giannini C; Judkins AR; Frühwald MC; Obser T; Schneppenheim R; Siebert R; Paulus W
Am J Surg Pathol; 2011 Jun; 35(6):933-5. PubMed ID: 21566516
[TBL] [Abstract][Full Text] [Related]
20. Rhabdoid tumor predisposition syndrome caused by SMARCB1 constitutional deletion: prenatal detection of new case of recurrence in siblings due to gonadal mosaicism.
Gigante L; Paganini I; Frontali M; Ciabattoni S; Sangiuolo FC; Papi L
Fam Cancer; 2016 Jan; 15(1):123-6. PubMed ID: 26342593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
